Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas

American Journal of Hematology

Volumn 85, Issue 1, 2010, Pages 46-50

  Arcaini, Luca ^a   Merli, Michele ^a   Passamonti, Francesco ^a   Bruno, Raffaele ^a   Brusamolino, Ercole ^a   Sacchi, Paolo ^a   Rattotti, Sara ^a   Orlandi, Ester ^a   Rumi, Elisa ^a   Ferretti, Virginia ^a   Rizzi, Silvia ^a   Meli, Erika ^a   Pascutto, Cristiana ^a   Paulli, Marco ^a   Lazzarino, Mario ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKYLATING AGENT; ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; HEPATITIS B SURFACE ANTIGEN; PREDNISOLONE; RITUXIMAB; VINCRISTINE; VIRUS RNA; ANTINEOPLASTIC AGENT; BIOLOGICAL FACTOR; CYTOTOXIN; MONOCLONAL ANTIBODY;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER IMMUNOTHERAPY; DISEASE ASSOCIATION; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER FAILURE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION; DISEASE FREE SURVIVAL; FOLLOW UP; MIDDLE AGED; TOXIC HEPATITIS; VIROLOGY;

AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL FACTORS; CYTOTOXINS; DISEASE-FREE SURVIVAL; DRUG-INDUCED LIVER INJURY; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED;

EID: 74049084986     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21564     Document Type: Article

References (31)

1. Isaacson PG. Update on MALT lymphomas. Best Pract Res Clin Haematol 2005;18:57-68.
2. Ferreri AJ, Ernberg I, Copie-Bergman C. Infectious agents and lymphoma development: Molecular and clinical aspects. J Intern Med 2009;265:421-438.
3. Nieters A, Kallinowski B, Brennan P, et al. Hepatitis C and risk of lymphoma: Results of the European multicenter case-control study EPILYMPH. Gastroenterology 2006;131:1879-1886.
4. de Sanjose S, Benavente Y, Vajdic CM, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol 2008;6:451-458.
5. Schollkopf C, Smedby KE, Hjalgrim H, et al. Hepatitis C infection and risk of malignant lymphoma. Int J Cancer 2008;122:1885-1890.
6. Hermine O, Lefrere F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002;347:89-94.
7. Vallisa D, Bernuzzi P, Arcaini L, et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: A multicenter Italian experience. J Clin Oncol 2005;23:468-473.
8. Besson C, Canioni D, Lepage E, et al. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs. J Clin Oncol 2006;24:953-960.
9. Visco C, Arcaini L, Brusamolino E, et al. Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: Analysis of 156 patients from northern Italy. Ann Oncol 2006;17:1434-1440.
10. Ziakas PD, Karsaliakos P, Mylonakis E. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: A meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica 2009;94:998-1005.
11. Zuckerman E, Zuckerman T, Douer D, et al. Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer 1998;83:1224-1230.
12. Jaffe ES HN, Stein H, Vardiman JW. World Health Organization: Classification of Tumours. Tumours of Haematopoietic and Lymphoid Tissue. Lyon: IARC Press; 2001. pp 135-137.
13. Swerdlow SH CE, Harris NL, Jaffe ES, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008. pp 218-219.
14. Labarga P, Soriano V, Vispo ME, et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 2007;196:670-676.
15. Dizdar O, Tapan U, Aksoy S, et al. Liver dysfunction after chemotherapy in lymphoma patients infected with hepatitis C. Eur J Haematol 2008;80:381-385.
16. Kanamori H, Fukawa H, Maruta A, et al. Case report: Fulminant hepatitis C viral infection after allogeneic bone marrow transplantation. Am J Med Sci 1992;303:109-111.
17. Maruta A, Kanamori H, Fukawa H, et al. Liver function tests of recipients with hepatitis C virus infection after bone marrow transplantation. Bone Marrow Transplant 1994;13:417-422.
18. Nakamura Y, Motokura T, Fujita A, et al. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991. Cancer 1996;78:2210-2215.
19. Vento S, Cainelli F, Mirandola F, et al. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet 1996;347:92-93.
20. Luppi M, Longo G, Ferrari MG, et al. Clinico-pathological characterization of hepatitis C virus-related B-cell non-Hodgkin's lymphomas without symptomatic cryoglobulinemia. Ann Oncol 1998;9:495-498.
21. Markovic S, Drozina G, Vovk M, et al. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 1999;46:2925-2930.
22. Kawatani T, Suou T, Tajima F, et al. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Eur J Haematol 2001;67:45-50.
23. Locasciulli A, Bruno B, Alessandrino EP, et al. Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: A retrospective study by the Italian group for blood and marrow transplantation. Bone Marrow Transplant 2003;31:295-300.
24. Takai S, Tsurumi H, Ando K, et al. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy. Eur J Haematol 2005;74:158-165.
25. Aksoy S, Abali H, Kilickap S, et al. Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin's lymphoma patient. Clin Lab Haematol 2006;28:211-214.
26. Ennishi D, Terui Y, Yokoyama M, et al. Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy. Am J Hematol 2008;83:59-62.
27. Hsieh CY, Huang HH, Lin CY, et al. Rituximab-induced hepatitis C virus reactivation after spontaneous remission in diffuse large B-cell lymphoma. J Clin Oncol 2008;26:2584-2586.
28. Kawatani T, Tajima F, Ishiga K, et al. Liver dysfunction in patients with acute myelogenous leukemia: Studies on patients not infected with hepatitis C virus during intense therapy. J Med 1998;29:45-56.
29. Peffault de Latour R, Levy V, Asselah T, et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood 2004;103:1618-1624.
30. Bellentani S, Pozzato G, Saccoccio G, et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: Report from the Dionysos study. Gut 1999;44:874-880.
31. Remstein ED, Kurtin PJ, Buno I, et al. Diagnostic utility of fluorescence in situ hybridization in mantle-cell lymphoma. Br J Haematol 2000;110:856-862.